Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01093 CSPC PHARMA
RTNominal up4.420 +0.050 (+1.144%)
Research Report

01/12/2023 15:32

{I-bank focus}UBS lowers CSPC Pharma (01093) to HKD10.6

[ET Net News Agency, 1 December 2023] UBS lowered its price target for CSPC Pharma
(01093) to HKD10.6 from HKD11.1 and maintained its "buy" rating.
The research house said it revises up revenue estimates for 2023-25E by 1.3%/1.2%/0.7%
to reflect more positive view on finished drugs.
Also, it trims SG&A expenses while raising R&D expenses, leading to higher S/T and lower
L/T EPS. (RC)

Back to Research Report

Remark: Real time quote last updated: 24/01/2025 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2025 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.